Related Experiment Video

Updated: Feb 16, 2026

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.5K

Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population

Feng Zang1, Ming Yue2, Yinan Yao1

  • 1Department of Epidemiology and Biostatistics,Key Laboratory of Infectious Diseases, School of Public Health,Nanjing Medical University,Nanjing 211166,China.

Epidemiology and Infection
|December 23, 2017
PubMed

Insights

Genetic variations in IL28B and MxA influence hepatitis C virus (HCV) chronicity and treatment response in Chinese patients. Specific genotypes are linked to higher chronicity risk and lower sustained virological response rates to pegylated interferon-alfa/ribavirin therapy.

Area of Science:

  • Genetics
  • Virology
  • Immunology

Background:

  • Chronic hepatitis C (CHC) poses a significant global public health challenge.
  • Interferon-lambda (IFN-λ) related genes play a crucial role in both spontaneous and treatment-induced hepatitis C virus (HCV) clearance.
  • Understanding genetic factors influencing HCV outcomes is vital for personalized treatment strategies.

Purpose of the Study:

  • To investigate the association between interleukin 28B (IL28B) and myxovirus resistance A (MxA) gene polymorphisms and HCV spontaneous clearance.
  • To evaluate the impact of these polymorphisms on the therapeutic response to pegylated interferon-alfa and ribavirin (pegIFN-α/RBV) in Chinese CHC patients.

Main Methods:

  • Genotyping of IL28B and MxA single nucleotide polymorphisms (SNPs) was performed using established methods.
  • Case-control study design involving CHC carriers, individuals with spontaneous HCV clearance, and CHC patients undergoing treatment.
  • Statistical analysis, including odds ratios (OR) and confidence intervals (CI), was used to assess associations.

Main Results:

  • The MxA rs2071430 TT genotype was associated with an increased likelihood of HCV chronicity (OR 1.22, P=0.042).
  • IL28B rs1298075 variant genotypes (OR 0.58, P=0.040) and MxA rs17000900 variant genotypes (OR 0.54, P=0.048) were linked to a lower probability of achieving sustained virological response (SVR).
  • Patients with IL28B rs1298075 AG genotype showed slower viral load reduction, while IL28B rs12980275 AA carriage positively impacted treatment response to pegIFN-α/RBV.

Conclusions:

  • IL28B and MxA gene polymorphisms are significant predictors of HCV chronicity and treatment outcomes in the Chinese population.
  • Specific MxA genotypes increase the risk of developing chronic HCV infection.
  • IL28B and MxA genotypes influence the efficacy of pegIFN-α/RBV therapy, highlighting their potential as biomarkers for treatment response.

Keywords:
IL28BMxAChronic hepatitis Cspontaneous clearancetreatment response

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.4K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.8K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
12
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
633